Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. EvoLife Wellness
WARNING LETTER
•EvoLife Wellness•August 31, 2025

EvoLife Wellness – FDA Warning Letter, Aug 31, 2025

Record Details

The FDA issued a warning letter to EvoLife Wellness on September 9, 2025, following a review of their website in August 2025. The inspection revealed that EvoLife Wellness offers compounded drug products, including semaglutide and tirzepatide, with misleading claims. These claims suggest equivalence to FDA-approved products, which is false, leading to the misbranding of these drugs under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA). The introduction of these misbranded products into interstate commerce violates section 301(a) of the FDCA.

The FDA requires EvoLife Wellness to take immediate corrective actions, including ceasing the use of misleading language that misbrands the products. The company must submit a written response within 15 working days, detailing steps taken to address and prevent future violations, along with supporting documentation. Failure to comply may result in legal actions, such as product seizure or injunctions.

EvoLife Wellness is responsible for ensuring compliance with all federal laws and FDA regulations. If the company believes its products are not in violation, it must provide reasoning and evidence. Correspondence should be directed to the Office of Compounding Quality and Compliance, with the subject line indicating a response to the warning letter.

Company
EvoLife Wellness
Inspection date
August 31, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • George Tidmarsh (Director)
View Company Profile

ID · 8bf35d0f-1829-4efe-8493-56d7a55658e7

Violation Codes10
21 U.S.C. 321(g)21 U.S.C. 352(bb)21 U.S.C. 331(c)21 U.S.C. 321(p)FD&C Act 502(a)FD&C Act 301(a)FD&C Act 201(g)FD&C Act 502(b)21.U.S.C. 331(a)21 U.S.C. 352(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore EvoLife Wellness
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.